儿童和青少年糖尿病前期及2型糖尿病筛查:美国预防服务工作组证据报告与系统评价
本系统评价为美国预防服务工作组(USPSTF)提供证据,纳入8篇出版物(856名参与者,平均年龄14岁,范围10-17岁),其中6篇来自TODAY研究。没有合格研究直接评价筛查的获益或危害。TODAY试验(699名肥胖青少年,平均年龄14岁)比较二甲双胍、二甲双胍+罗格列酮、二甲双胍+生活方式干预,近期诊断糖尿病者中肾脏损害分别为0例 vs 1例 vs 1例(P > .99),糖尿病酮症酸中毒分别为5例 vs 3例 vs 3例(P = .70)。另一项75名肥胖糖尿病前期青少年(平均年龄13岁)的随机对照试验比较强化生活方式干预与标准治疗,6个月随访期间两组均无参与者发展为糖尿病。干预危害方面,严重低血糖事件报告率低于1%,二甲双胍+罗格列酮组轻微低血糖事件更常见(8.2% vs 4.3% vs 3.4%,P = .05)。
要点
- 无合格研究直接评价儿童青少年糖尿病前期及2型糖尿病筛查的获益或危害。
- TODAY试验中近期诊断糖尿病者肾脏损害分别为二甲双胍0例、二甲双胍+罗格列酮1例、二甲双胍+生活方式干预1例(P > .99)。
- TODAY试验中糖尿病酮症酸中毒分别为二甲双胍5例、二甲双胍+罗格列酮3例、二甲双胍+生活方式干预3例(P = .70)。
- 75名肥胖糖尿病前期青少年的随机对照试验中,强化生活方式干预组与标准治疗组6个月随访均无参与者发展为糖尿病。
- TODAY试验中二甲双胍+罗格列酮组轻微低血糖事件更常见(8.2% vs 4.3% vs 3.4%,P = .05),严重低血糖事件报告率低于1%。
适用人群与场景
- 儿童和青少年(平均年龄14岁,范围10-17岁),包括肥胖青少年和近期诊断的2型糖尿病或糖尿病前期青少年。
- 证据来源于筛查或干预研究,未限定急诊或ICU场景。
处置流程与药物剂量
- 一项随机对照试验比较强化生活方式干预与标准治疗,用于肥胖糖尿病前期青少年(原文未给出具体方案细节)。
研究设计与关键结果
- 系统评价纳入8篇出版物(856名参与者;平均年龄14岁,范围10-17岁),其中6篇来自TODAY研究。
- 无合格研究直接评价筛查的获益或危害。
- TODAY试验(n = 699名肥胖青少年;平均年龄14岁)比较二甲双胍、二甲双胍+罗格列酮、二甲双胍+生活方式干预:近期诊断糖尿病者中肾脏损害分别为0例 vs 1例 vs 1例(P > .99);糖尿病酮症酸中毒分别为5例 vs 3例 vs 3例(P = .70)。
- 一项随机对照试验(n = 75名肥胖糖尿病前期青少年;平均年龄13岁)比较强化生活方式干预与标准治疗:6个月随访期间两组均无参与者发展为糖尿病。
- 危害:严重低血糖事件报告率低于1%;TODAY试验中轻微低血糖事件在二甲双胍+罗格列酮组更常见(8.2% vs 4.3% vs 3.4%,P = .05);一项研究中二甲双胍组胃肠道不良事件报告率高于安慰剂组(腹痛:25% vs 12%;恶心/呕吐:17% vs 10%;P未报告)。
证据类型、等级与局限
- 证据类型:美国预防服务工作组(USPSTF)证据报告与系统评价;纳入随机对照试验等对照研究,采用定性合成。
- 局限:无合格研究直接评价筛查的获益或危害;仅有的合格试验报告的健康结局很少且组间无差异;证据受限于 substantial imprecision(显著不精确性)和随访时间可能不足以评估健康结局。
对床旁实践的改变
- 原文未据此给出推荐;作者指出无合格研究直接评价儿童青少年糖尿病前期及2型糖尿病筛查的获益或危害,仅有的干预试验报告结局少且组间无差异,证据受限于显著不精确性和随访时间可能不足以评估健康结局。
指南或共识出处
- 美国预防服务工作组(USPSTF)证据报告与系统评价,发表于JAMA。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Of youths diagnosed with type 2 diabetes, many develop microvascular complications by young adulthood.
OBJECTIVE: To review the evidence on benefits and harms of screening children and adolescents for prediabetes and type 2 diabetes to inform the US Preventive Services Task Force (USPSTF).
DATA SOURCES: PubMed/MEDLINE, Cochrane Library, and trial registries through May 3, 2021; references; experts; literature surveillance through July 22, 2022.
STUDY SELECTION: English-language controlled studies evaluating screening or interventions for prediabetes or type 2 diabetes that was screen detected or recently diagnosed.
DATA EXTRACTION AND SYNTHESIS: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings.
MAIN OUTCOMES AND MEASURES: Mortality, cardiovascular morbidity, diabetes-related morbidity, development of diabetes, quality of life, and harms.
RESULTS: This review included 8 publications (856 participants; mean age, 14 years [range, 10-17 years]). Of those, 6 were from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. No eligible studies directly evaluated the benefits or harms of screening. One randomized clinical trial (RCT) (TODAY; n = 699 adolescents with obesity; mean age, 14 years) comparing metformin, metformin plus rosiglitazone, and metformin plus lifestyle intervention reported that 2 youths with recently diagnosed diabetes developed kidney impairment (0 vs 1 vs 1, respectively; P > .99) and 11 developed diabetic ketoacidosis (5 vs 3 vs 3, respectively; P = .70). One RCT of 75 adolescents (mean age, 13 years) with obesity with prediabetes compared an intensive lifestyle intervention with standard care and reported that no participants in either group developed diabetes, although follow-up was only 6 months. Regarding harms of interventions, 2 RCTs assessing different comparisons enrolled youths with recently diagnosed diabetes. Major hypoglycemic events were reported by less than 1% of participants. Minor hypoglycemic events were more common among youths treated with metformin plus rosiglitazone than among those treated with metformin or metformin plus lifestyle intervention in TODAY (8.2% vs 4.3% vs 3.4%, P = .05). In 1 study, gastrointestinal adverse events were more commonly reported by those taking metformin than by those taking placebo (abdominal pain: 25% vs 12%; nausea/vomiting: 17% vs 10%; P not reported).
CONCLUSIONS AND RELEVANCE: No eligible studies directly evaluated the benefits or harms of screening for prediabetes and type 2 diabetes in children and adolescents. For youths with prediabetes or recently diagnosed (not screen-detected) diabetes, the only eligible trials reported few health outcomes and found no difference between groups, although evidence was limited by substantial imprecision and a duration of follow-up likely insufficient to assess health outcomes.
参考来源
- Jonas DE, Vander Schaaf EB, Riley S, et al. Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 36098720. doi:10.1001/jama.2022.7957
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。